Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...

While metabolomics is the large-scale comprehensive profiling of metabolites and other small molecules in the context of ...

SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV ...

Jonathan Kotula: We think there needs to be a systems-level approach to deal with complex diseases such as cancer. A lot of what has been done so far are reductionist approaches—one small molecule for ...

Extending human health span by several years is the vision of clock.bio, a biotech startup that is investigating the biology of cellular rejuvenation. The company recently raised $5.3 million in seed ...